Chiesi USA, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$12Mgeneral payments (2019-2025)
$478Kresearch payments (2019-2025)
27,682clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Cleviprex $1.3M associated (2023-2025)
- Kengreal $809K associated (2023-2025)
- Mycapssa $508K associated (2023-2025)
- Elfabrio $323K associated (2023-2025)
- Lamzede $320K associated (2023-2025)
- Curosurf $308K associated (2023-2025)
- Ferriprox $249K associated (2023-2025)
- Filsuvez $243K associated (2023-2025)
- Juxtapid $126K associated (2023-2025)
- Revcovi $99K associated (2023-2025)
- Myalept $49K associated (2023-2025)
- Bronchitol $10K associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Marianne Mann | Highland, MD | Internal Medicine | $1,938,789.03 |
| David Rose | Tampa, FL | Neurology (Psychiatry & Neurology) | $402,489.35 |
| Gerald Cox | Boston, MA | Clinical Genetics (M.D.) | $332,110.00 |
| Todd Horowitz | Delray Beach, FL | Anesthesiology | $239,734.66 |
| Dawn Meyer | San Diego, CA | Family | $231,205.96 |
| Qais Abu Ali | Canton, OH | Internal Medicine | $198,712.50 |
| Megha Prasad | New York, NY | Cardiovascular Disease | $176,913.62 |
| Edward Obrien | Urbana, IL | Anesthesiology | $165,795.53 |
| William Alexander | Cary, NC | Infectious Disease | $160,901.99 |
| Fariborz Rezai | Livingston, NJ | Critical Care Medicine (Internal Medicine) | $142,636.03 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.